Tirzepatide (mounjaro) 5mg 10mg 15mg jekiseni

tsananguro pfupi:

Zita: Tirzepatide

Zvinyorwa: 5mg / vial * 10vials / bhokisi 10mg / vial * 10vial / bhokisi 15mg / bhobho * 10vial / bhokisi

Mutengo: 5mg USD110/bhokisi 10mg USD220/bhokisi 15mg USD330/bhokisi

Lab: Lianfu Bio

MOQ: 1 bhokisi

Tumira email kwatiri

Product Detail

Tirzepatide

Tirzepatide inoferefeta kamwechete pavhiki, mbiri yeglucose-inotsamira insulinotropic polypeptide uye glucagon-yakafanana peptide-1 receptor agonist inobatanidza zviito zveese incretins kuita imwe molecule.

Tirzepatide Mimics Natural Hormones iyo Inosimudzira Kunzwa Kwakazara
Tirzepatide inoshanda nekutevedzera iyo GLP-1 uye GIP mahomoni ayo anosikwa achivanzirwa nemudumbu mushure mekudya, izvo zvinosimudzira insulin secretion.Inoderedzawo kudya nekudzikisira nguva inotora dumbu kuti rive risina uye kupindirana nenzvimbo dziri muuropi dzinobata GLP-1 receptors kuratidza satiety.

Tirzepatide mushonga mutsva uyo FDA inotenderwa kurapwa kwemhando yechipiri chirwere cheshuga mellitus.Zvichipa simba rayo rekurasikirwa nehuremu zvimiro,tirzepatidekushandiswa off-label kurapwa kufutisa.Inoshanda seaviri GLP-1 agonist uye GIP agonist kuti awedzere mabhenefiti akafanana anoonekwa neGLP-1 mishonga yakadai semaglutide.Parizvino inoshandiswa semushonga wechipiri wechirwere cheshuga, wakafanana nemishonga yeGLP-1, uye inopihwa kamwe chete pasvondo subcutaneous jekiseni.

Tirzepatide ndeye glucose-inotsamira insulinotropic polypeptide (GIP) receptor uye glucagon-yakafanana peptide-1 (GLP-1) recepto agonist, inova inotenderwa neFDA kurapa rudzi rwechipiri chirwere cheshuga.Izvo zvakakosha kuti uzive kuti tirzepatide haina kubvumidzwa kurapa mhando-1 chirwere cheshuga mellitus uye haina kudzidzwa muvarwere vane pancreatitis.Tirzepatide iGIP receptor uye GLP-1 receptor agonist, inotungamira kune yakanyanya kunatsiridza glycemic control mumhando 2 chirwere cheshuga uye kwakakosha kudzikisa uremu.

Iyo FDA yakabvumidza Tirzepatide muna Chivabvu 2022. Tirzepatide inogona zvakare kushandiswa kure-label kurapa kufutisa.Ikozvino inoshandiswa sechipiri-mutsara wechirwere cheshuga, wakafanana nemishonga yeGLP-1 semaglutide.Iro kamwe-pa-svondo subcutaneous jekiseni mishonga ine incremental dose inowedzera.

Yazvino data yekiriniki yakaratidza kuti tirzepatide inopfuura placebo mukuvandudza hemoglobin A1C mazinga.The SURPASS-5 kliniki yekuedza yakaratidza -2.11% kuderedza hemoglobin A1C mazinga pa 5mg pavhiki dosing, zvichienzaniswa -0.86% ne placebo.Pachiyero chepamusoro che 15 mg pavhiki, tirzepatide yakatungamirira ku -2.34% kuderedza muhemoglobin A1C.Izvi zvakaratidzwa kwemavhiki makumi mana.Kuderedza uremu hwe5.4 kg kwakaonekwa ne5mg yetirzepatide dosing, uye kuderedzwa kwe10.5 kg kwakaonekwa ne 15 mg dosing.Iyi dhigirii-inotsamira kuwirirana nekurasikirwa nehuremu yakafanana nesemaglutide, yakajairika GLP-1 mishonga inoshandiswa pakuremerwa uremu.

Sezvineiwo, tirzepatide yakaratidza kushanda zvakafanana kune GLP-1 mishonga asi nekubudirira kukuru.Zvichipa uremu hwayo huremu uye kushaikwa kwechiropa chehupfu, zvinogona kuita zvisina kunanga basa mukurapa kwe-nonalcoholic fatty chiropa chirwere (NAFLD) zvakare.